How much is BioMarin Pharmaceutical worth in 2026?

BioMarin Pharmaceutical has a current valuation of N/A based on their PIPE round and secondary market data.

How much funding has BioMarin Pharmaceutical raised?

BioMarin Pharmaceutical has raised N/A in total funding across 1 funding rounds.

BioMarin Pharmaceutical

Drug Discovery

BioMarin Pharmaceutical valuation and funding history | Last updated: September 20, 2024 | 1 funding rounds

Current Valuation

N/A

As of September 20, 2024

Total Funding Raised

N/A

Across 1 round

Last Round

PIPE

$689.5M

Last Funding

Sep 2024

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
September 20, 2024	PIPE	$689.5M	N/A	-

Valuation Analysis

Current Valuation Metrics

BioMarin Pharmaceutical is currently valued at N/A as of September 20, 2024.

Track BioMarin Pharmaceutical Valuation Updates

Get notified when BioMarin Pharmaceutical raises new funding or valuation changes

Explore More Data

Detailed analysis for BioMarin Pharmaceutical

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock BioMarin Pharmaceutical's valuation history, funding rounds, and growth metrics.

No credit card required

What is BioMarin Pharmaceutical Worth in 2026?

BioMarin Pharmaceutical is a leading private company in the Drug Discovery sector. Track BioMarin Pharmaceutical's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How BioMarin Pharmaceutical Valuation is Determined

Private company valuations like BioMarin Pharmaceutical's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.